Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis
Scientific Reports · 2024
DOI: 10.1038/s41598-024-66064-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Scientific Reports, 2024. Verfasst von Koichi Murata und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo, Kyoto, 606-8507…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Interleukin-6, Abatacept, Antirheumatic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
This study aims to identify factors influencing the alleviation of knee joint symptoms in patients with rheumatoid arthritis treated with biologic or target synthetic disease-modifying antirheumatic drugs (b/tsDMARDs). Among 2321 patients who started b/tsDMARDs between 2010 and 2023, we focused on 295 patients who had knee swelling or tenderness at the initiation of b/tsDMARDs and continued b/tsDMARDs at least 3 months, with recorded knee symptoms 6 months later. Symptom relief after 6 months was 78.2% for interleukin 6 (IL-6) inhibitors, 68.6% for Janus kinase (JAK) inhibitors, 65.8% for tumor necrosis factor (TNF) inhibitors, and 57.6% for cytotoxic T lymphocyte-associated antigen-4-Ig (CTLA4-Ig). The initial use of b/tsDMARDs and the use of IL-6 inhibitors in comparison to CTLA4-Ig emerged as a significant factor associated with the improvement of knee joint symptoms. Among 141 patients who underwent knee radiography at baseline and two years later, the deterioration in knee joint radiographs was 7.7% for IL-6 inhibitors, 6.3% for JAK inhibitors, 21.9% for TNF inhibitors, and 25.9% for CTLA4-Ig. The use of IL-6 inhibitors was a significant factor associated with the improvement of knee joint symptoms and the inhibition of joint destruction compared to CTLA4-Ig.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo, Kyoto, 606-8507, Japan. kchm@kuhp.kyoto-u.ac.jp.
- Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Sakyo, Kyoto, Japan. kchm@kuhp.kyoto-u.ac.jp.
- Department of Industrial Engineering and Economics, Tokyo Institute of Technology, Tokyo, 152-8552, Japan.
- Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 54 Shogoin-Kawahara-cho, Sakyo, Kyoto, 606-8507, Japan.
- Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Sakyo, Kyoto, Japan.
- Division of Clinical Immunology and Cancer Immunotherapy, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of Medicine, Sakyo, Kyoto, 606-8501, Japan.
Zitieren
APA
Murata, K., Uozumi, R., Fujii, T., Onishi, A., Murakami, K., Onizawa, H., Tanaka, M., Morinobu, A., & Matsuda, S. (2024). Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis. Scientific Reports. https://doi.org/10.1038/s41598-024-66064-3
Vancouver
Murata K, Uozumi R, Fujii T, Onishi A, Murakami K, Onizawa H, et al. Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis. Scientific Reports. 2024. doi:10.1038/s41598-024-66064-3
BibTeX
@article{Murata2024,
author = {Murata, Koichi and Uozumi, Ryuji and Fujii, Takayuki and Onishi, Akira and Murakami, Kosaku and Onizawa, Hideo and Tanaka, Masao and Morinobu, Akio and Matsuda, Shuichi},
title = {Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis},
journal = {Scientific Reports},
year = {2024},
doi = {10.1038/s41598-024-66064-3}
}
EUVIMED